Ghulam Rehman Mohyuddin

Oct 15, 2024 | nature.com | Ghulam Rehman Mohyuddin |Rajshekhar Chakraborty |Samer Al Hadidi

Dear Editor,Humans rely on heuristics to simplify decision-making [1] and often use chronological age as a key factor. However, chronological age may not accurately reflect an individual’s physiological age and functional performance [2]. A notable heuristic in decision-making is left-digit bias, where humans tend to categorize decisions based on the left-most digit of a continuous variable (e.g., age, blood pressure) [3].

Aug 11, 2024 | nature.com | Rajshekhar Chakraborty |Aniko Szabo |Carolina Schinke |Binod Dhakal |Ghulam Rehman Mohyuddin |Martin Kaiser | +1 more

To the Editor:Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma [MM], with single-agent response rates from 57–71% [1,2,3,4,5,6].

Apr 22, 2024 | nature.com | Ghulam Rehman Mohyuddin

Certain subsets of patients with multiple myeloma or its precursor conditions are overtreated with current approaches to therapy. Herein, we highlight several key areas where we believe de-escalation of treatment is needed. Dedicated trials to assess these de-escalation approaches and urgent changes to current clinical practices are needed.

May 10, 2023 | ecancer.org | Manju Sengar |Wilma M Hopman |Ghulam Rehman Mohyuddin |Aaron Goodman

How likely is this article to improve patient care in your region? Is reading this article likely to improve your clinical practice? How likely are you to recommend this article to a colleague?

May 10, 2023 | ecancer.org | Manju Sengar |Wilma M Hopman |Ghulam Rehman Mohyuddin |Aaron Goodman

Background: Design, results, and interpretation of oncology randomised controlled trials (RCTs) have changed substantially over the past decade. In this study, we describe all RCTs evaluating anticancer therapies in haematological cancers published globally during 2014–2017 with comparisons with solid tumours RCTs. Methods: A PubMed literature search identified all phase 3 RCTs of anticancer therapy for haematological cancers and solid tumours published globally during 2014–2017.